Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

[1]  S. Yamagishi,et al.  Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. , 2010, Pharmacological research.

[2]  K. Chayama,et al.  Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. , 2008, Metabolism: clinical and experimental.

[3]  S. Yamagishi,et al.  Advanced glycation end products (AGEs) and their involvement in liver disease. , 2008, Current pharmaceutical design.

[4]  T. Imaizumi,et al.  Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetes , 2008, Diabetes/metabolism research and reviews.

[5]  K. Chayama,et al.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells , 2008, Journal of Gastroenterology.

[6]  T. Imaizumi,et al.  Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects , 2007, Clinical and Experimental Medicine.

[7]  K. Chayama,et al.  Elevated levels of serum advanced glycation end products in patients with non‐alcoholic steatohepatitis , 2007, Journal of gastroenterology and hepatology.

[8]  T. Imaizumi,et al.  Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes , 2006, Clinical and Experimental Medicine.

[9]  K. Tsuneyama,et al.  Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis , 2006, Journal of Gastroenterology.

[10]  J. Gisbert,et al.  A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients , 2006, Alimentary pharmacology & therapeutics.

[11]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[12]  N. Yoshiike,et al.  Epidemiological aspects of obesity and NASH/NAFLD in Japan. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[14]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[15]  G. Lazaraki,et al.  Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[16]  K. Lindor,et al.  Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[17]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[18]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[19]  稲垣 洋介.  Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation , 2004 .

[20]  S. Gurel,et al.  Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  E. Van Obberghen,et al.  Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling through a Protein Kinase Cα-mediated Mechanism* , 2003, Journal of Biological Chemistry.

[22]  J. Hui,et al.  Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them , 2003, Journal of Gastroenterology and Hepatology.

[23]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[24]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[25]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[26]  T. Imaizumi,et al.  Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. , 2003, International journal of clinical pharmacology research.

[27]  Z. Makita,et al.  Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. , 2002, Biochemical and biophysical research communications.

[28]  K. Miyata,et al.  Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. , 2002, Biochimica et biophysica acta.

[29]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[30]  Hiroshi Yamamoto,et al.  Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. , 2002, Biochemical and biophysical research communications.

[31]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[32]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[33]  P. Aspichueta,et al.  Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. , 2000, Atherosclerosis.

[34]  K. Kawasaki,et al.  Roles of the AGE‐RAGE System in Vascular Injury in Diabetes a , 2000, Annals of the New York Academy of Sciences.

[35]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[36]  R. Bucala,et al.  Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo , 2000, Molecular medicine.

[37]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[38]  C. Day,et al.  Non-alcoholic steatohepatitis: another disease of affluence , 1999, The Lancet.

[39]  C. Bisgaier,et al.  Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. , 1998, Atherosclerosis.

[40]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.

[41]  D. Whalan.  The ethics and morality of clinical trials in man. , 1975, The Medical journal of Australia.